Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 in progressive fibrosing interstitial lung diseases (PF-ILDs, non-IPF)
jRCT2031220475Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of nerandomilast in progressive pulmonary fibrosis (PPF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Absolute change from baseline in forced vital capacity at Week 52. Started Dec 2022; status: completed.
02
Drugs
nerandomilast
03
Conditions
progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on jRCT2031220475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220475.